Medesis Pharma S.A.

As of December 31, 2023, Medesis Pharma S.A. has 4.96M shares outstanding.

These figures are as of December 31, 2023. The EV/Sales ratio of 3.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Medesis Pharma S.A. trades at an EV/FCF ratio of 5.05, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2023, Medesis Pharma S.A. maintains a current ratio of 0.38, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -26.67, indicating conservative leverage, while an interest coverage ratio of -16.60 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -206.12, reflecting losses generated across the asset base. Inventory turnover of 20.09 indicates how many times Medesis Pharma S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on April 7, 2025, Medesis Pharma S.A.'s stock has declined approximately 76.35% over the past 52 weeks. The 50-day moving average sits at 0.37, while the 200-day moving average is 0.51.

Over the twelve months ended December 31, 2023, Medesis Pharma S.A. posted a gross margin of -888.16, reflecting its pricing power and cost economics. The operating margin of -1,409.62 and net profit margin of -1,319.68 provide insight into operational efficiency.

As of December 31, 2023, Medesis Pharma S.A. has an Altman Z-Score of -24.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.